We Offer Worldwide Shipping
Login Wishlist

Andrographolide

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-A3015

  • Specification : 98%

  • CAS number : 5508-58-7

  • Formula : C20H30O5

  • Molecular Weight : 350.45

  • PUBCHEM ID : 5318517

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-A3015

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

-20℃

Molecular Weight

350.45

Appearance

White crystalline powder

Botanical Source

Andrographis paniculata

Structure Type

Terpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O

Synonyms

ANDROGRAPHIS/Rhizoma Sparganii/Andrographolid/ANDRO/Andrographalide/Andrographolide

IUPAC Name

(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one

Density

1.2±0.1 g/cm3

Solubility

Methanol

Flash Point

195.5±23.6 °C

Boiling Point

557.3±50.0 °C at 760 mmHg

Melting Point

229-232ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932200000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:5508-58-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

27896563

Abstract

Andrographolide, a diterpenoid, is known for its anti-inflammatory effects. It can be isolated from various plants of the genus Andrographis, commonly known as ‘creat’. This purified compound has been tested for its anti-inflammatory effects in various stressful conditions, such as ischemia, pyrogenesis, arthritis, hepatic or neural toxicity, carcinoma, and oxidative stress, Apart from its anti-inflammatory effects, andrographolide also exhibits immunomodulatory effects by effectively enhancing cytotoxic T cells, natural killer (NK) cells, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). All these properties of andrographolide form the foundation for the use of this miraculous compound to restrain virus replication and virus-induced pathogenesis. The present article covers antiviral properties of andrographolide in variety of viral infections, with the hope of developing of a new highly potent antiviral drug with multiple effects.

Title

Broad-spectrum antiviral properties of andrographolide.

Author

Gupta S1, Mishra KP2, Ganju L1.

Publish date

2017 Mar

PMID

28034742

Abstract

Dengue is the most prevalent arthropod-transmitted viral illness of humans, with an estimated 100 million symptomatic infections occurring each year and more than 2.5 billion people living at risk of infection. There are no approved antiviral agents against dengue virus, and there is only limited introduction of a dengue vaccine in some countries. Andrographolide is derived from Andrographis paniculata, a medicinal plant traditionally used to treat a number of conditions including infections. The antiviral activity of andrographolide against dengue virus (DENV) serotype 2 was evaluated in two cell lines (HepG2 and HeLa) while the activity against DENV 4 was evaluated in one cell line (HepG2). Results showed that andrographolide had significant anti-DENV activity in both cell lines, reducing both the levels of cellular infection and virus output, with 50% effective concentrations (EC50) for DENV 2 of 21.304 μM and 22.739 μM for HepG2 and HeLa respectively. Time of addition studies showed that the activity of andrographolide was confined to a post-infection stage. These results suggest that andrographolide has the potential for further development as an anti-viral agent for dengue virus infection.

Copyright © 2016 Elsevier B.V. All rights reserved.

KEYWORDS

Andrographis paniculata; Andrographolide; Antiviral; Dengue virus

Title

Activity of andrographolide against dengue virus.

Author

Panraksa P1, Ramphan S1, Khongwichit S1, Smith DR2.

Publish date

2017 Mar

PMID

29983086

Abstract

CONTEXT:
Andrographolide and warfarin are often used together in clinics in China. However, the herb-drug interaction between andrographolide and warfarin is still unknown.

OBJECTIVE:
This study investigates the herb-drug interaction between andrographolide and warfarin in vivo and in vitro.

MATERIALS AND METHODS:
A sensitive and reliable LC-MS/MS method was developed for the determination of warfarin in male Sprague-Dawley rats plasma, and then the pharmacokinetics of orally administered warfarin (0.5 mg/kg) with or without andrographolide (30 mg/kg/day for 7 days) pretreatment was investigated. In addition, Sprague-Dawley rat liver microsomes incubation systems were used to support the in vivo pharmacokinetic data and investigate its potential mechanism.

RESULTS:
The method validation results showed that a sensitive and reliable LC-MS/MS method was developed for the determination of warfarin in rat plasma samples. The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h). Additionally, the metabolic stability of warfarin increased from 23.5 ± 4.7 to 38.7 ± 6.1 min with the pretreatment of andrographolide, and the difference was significant (p < 0.05).

DISCUSSION AND CONCLUSION:
In conclusion, andrographolide could increase the systemic exposure of warfarin in rats when andrographolide and warfarin were co-administered, and possibly by slowing down the metabolism of warfarin in rat liver by inhibiting the activity of CYP3A4 or CYP2C9.

KEYWORDS

Herb-drug interaction; LC-MS/MS; metabolism

Title

Influence of andrographolide on the pharmacokinetics of warfarin in rats.

Author

Zhang X1,2, Zhang X1, Wang X1, Zhao M2.

Publish date

2018 Dec


Description :

Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation.